Details

Autor(en) / Beteiligte

• Tatenuma, Tomoyuki
• Miyamoto, Hiroshi

Titel

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Ist Teil von

• Drug design, development and therapy, 2023-01, Vol.17, p.2325-2333

Ort / Verlag

New Zealand: Dove Medical Press Limited

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Androgen deprivation therapy, primarily via a gonadotropin-releasing hormone receptor agonist or antagonist together with or without an androgen receptor antagonist, remains the mainstay of medical treatment for advanced prostate cancer. Meanwhile, relugolix has been developed as the first orally active, non-peptide, selective antagonist for the gonadotropin-releasing hormone receptor. Previous randomized studies involving patients with prostate cancer have demonstrated comparable efficacy in androgen suppression between relugolix vs other gonadotropin-releasing hormone antagonists or agonists. This review summarizes available data on the design and development of relugolix and its therapeutic application, and discusses if relugolix represents a promising oral alternative to injectable androgen deprivation therapy. Based on current published evidence, further investigation is likely required to determine the actual clinical benefits of relugolix therapy against prostate cancer.